摘要
目的观察达比加群治疗肺心病并房颤的临床疗效。方法选取符合标准的慢性肺源性心脏病合并房颤100例,所有患者均给予规范化治疗,在此基础上50例使用华法林,50例使用达比加群,观察患者用药后脑梗塞、脑出血、皮肤及皮下出血、尿潜血、大便潜血(OB)、血小板(PLT)、凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)、国际标准化比值(INR)、纤维蛋白原(FBG)、D-二聚体测定(D-D)、纤维蛋白原降解物(FDP)、抗凝血酶(AT3)的改变。结果应用达比加群组的出血情况明显少于华法林组,差异有统计学意义(P<0.05)。结论达比加群用于肺心病房颤患者抗凝治疗疗效好,出血事件少,安全性高。
Objective The purpose of the research is to observe the clinical efficacy of dabigatran in the treatment of atrial fibrillation in pulmonary heart disease.Method 100 cases of patients with atrial fibrillation of chronic pulmonary heart disease were selected and the standardized treatment was given to them.On this basis,Warfarin was used in 50 cases,dabigatran in 50 cases to observe the changes in the patients'cerebral infraction,cerebal hemorrhage,skin and subcutaneous bleeding,urinary occult blood,fecal occult blood,platelets,prothrombin time,partial activated prothrombin time,international normalized ratio,fibrinogen,D-2 polymer determination,fibrinogen degradants and antihemagglutinase.Results The bleeding of dabigat group was significantly less than that of warfarin group;the difference was statistically significant(P<0.05).Conclusion It indicates that the application and the treatment of dabigatran in patients with atrial fibrillation and pulmonary heart disease can significantly reduce the anticoagulant bleeding and have a high safety.
作者
王旭
戴海龙
WANG Xu;DAI Hai-long(Dept.of Emergency Medicine,Yan'an Hospital Affiliated to Kunming Medical University;Dept.of Cardiology,Key Laboratory of Cardiovascular Disease of Yunnan Province,Kunming Yunnan 650051,China)
出处
《昆明医科大学学报》
CAS
2020年第9期45-49,共5页
Journal of Kunming Medical University
基金
国家自然科学基金资助项目(81700438)
云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目[2017FE467-(199)]。
关键词
肺心病
房颤
达比加群
华法林
Cor Pulmonale
Atrial fibrillation
Dabigatran
Warfarn
